Neutralizing anti-influenza A antibodies and uses thereof
The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
1. An isolated antibody or a binding fragment thereof that is capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus, wherein the antibody or fragment thereof includes a set of six CDRs which includes HCDR1 of SEQ ID NO.: 113, HCDR2 of SEQ ID NO.: 114, HCDR3 of SEQ ID NO.: 115, LCDR1 of SEQ ID NO.: 118, LCDR2 of SEQ ID NO.: 119 and LCDR3 of SEQ ID NO.: 120.
2. The antibody or binding fragment according to claim 1 , wherein the antibody or binding fragment is capable of neutralizing one or more influenza A virus group 1 subtype selected from: H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and variants thereof; and one or more influenza A virus group 2 subtypes selected from: H3, H4, H7, H10, H14 and H15 and variants thereof.
3. The antibody or binding fragment thereof according to claim 1 , wherein the antibody or binding fragment is capable of neutralizing group 1 subtypes: H1, H2, H5, H6 and H9 and group 2 subtypes H3 and H7; or wherein the antibody or binding fragment is capable of neutralizing group 1 subtypes: H1, H2, H5 and H6 and group 2 subtypes H3 and H7.
4. The antibody or binding fragment thereof according to claim 1 , wherein the antibody or binding fragment has high neutralizing potency expressed as 50% inhibitory concentration (IC 50 ug/ml) in the range of from about 0.01ug/ml to about 50ug/ml of antibody for neutralization of influenza A virus in a microneutralization assay.
5. The antibody or binding fragment thereof according to claim 1 comprising a VH having at least 75% identity and/or a VL having at least 75% identity to a VH of SEQ ID NO.: 112 and a VL of SEQ ID NO.: 117.
6. The antibody or binding fragment thereof according to claim 1 comprising a VH of SEQ ID NO.: 112 and a VL of SEQ ID NO.: 117.
7. The antibody or binding fragment thereof according to claim 1 , wherein the antibody or binding fragment is selected from the group consisting of: an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody, a diabody, a multispecific antibody, a dual-specific antibody, and a bispecific antibody.
8. The antibody or binding fragment thereof according to claim 1 , wherein the VH comprises human germline framework VH6-1, the VL comprises human germline framework VK1-39, and combination thereof.
9. The antibody or binding fragment thereof according to claim 1 comprising an Fc region.
10. The antibody or binding fragment thereof according to claim 1 , wherein the antibody is an IgG1, IgG2 or IgG4 or fragment thereof.
11. An isolated nucleic acid encoding an antibody or binding fragment thereof according to claim 1 .
12. A vector comprising an isolated nucleic acid according to claim 11 .
13. A host cell comprising a nucleic acid according to claim 11 .
14. A composition comprising an antibody or binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.
15. A composition comprising an antibody or binding fragment thereof according to claim 1 comprising 25mM His and 0.15M NaCl at pH 6.0.